Mkt Cap$2.30T-1.81%
24h Vol$85.33B
BTC Dom56.1%
ETH Dom9.2%
F&G22Extreme Fear
BTC$64,333.00-1.99% ETH$1,744.09-2.59% USDT$0.9992+0.00% BNB$600.17-0.85% USDC$0.9997-0.01% XRP$1.19-2.62% SOL$71.84-2.49% TRX$0.3205+1.27% FIGR_HELOC$1.02-1.28% HYPE$71.30-2.33% DOGE$0.0858-1.59% USDS$0.9997+0.00% RAIN$0.0146+3.03% LEO$9.68-0.32% ZEC$482.28-5.08% XLM$0.2284+4.51% BTC$64,333.00-1.99% ETH$1,744.09-2.59% USDT$0.9992+0.00% BNB$600.17-0.85% USDC$0.9997-0.01% XRP$1.19-2.62% SOL$71.84-2.49% TRX$0.3205+1.27% FIGR_HELOC$1.02-1.28% HYPE$71.30-2.33% DOGE$0.0858-1.59% USDS$0.9997+0.00% RAIN$0.0146+3.03% LEO$9.68-0.32% ZEC$482.28-5.08% XLM$0.2284+4.51%
News

AMRX

Total Stories
1
Section
AMRX
Amneal Pharmaceuticals (AMRX) Reports $617 Million in Q4 Revenue, Eyes Growth in 2024
Earnings

Amneal Pharmaceuticals (AMRX) Reports $617 Million in Q4 Revenue, Eyes Growth in 2024

Amneal Pharmaceuticals Inc. reported a slight increase in net revenue to $617 million for Q4 2023.

Tim FriesMar 1, 20242 min read